1039046-51-9

Basic information

• Product Name: 4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline
• Synonyms: 4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline
• CAS NO: 1039046-51-9
• Molecular Weight: 314.273
• Mol File: 1039046-51-9.mol

Chemical Properties

• CAS DataBase Reference: 4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline(1039046-51-9)
• EPA Substance Registry System: 4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline(1039046-51-9)

Safety Data

• Hazardous Substances Data: 1039046-51-9(Hazardous Substances Data)

Upstream product

• 68500-37-8 4-chloro-7-methoxyquinoline 
• 403-19-0 2-fluoro-4-nitrophenol 

Downstream Products

• 913376-57-5 3-fluoro-4-(7-methoxyquinolin-4-yloxy)benzenamine 
• 1394821-00-1 1-((4-(4-amino-2-fluorophenoxy)quinolin-7-yl)oxy)-2-methylpropan-2-ol 
• 1394821-01-2 4-(4-amino-2-fluorophenoxy)quinolin-7-ol 
• 1394820-99-5 1-((4-(2-fluoro-4-nitrophenoxy)quinolin-7-yl)oxy)-2-methylpropan-2-ol 
• 1394820-98-4 4-(2-fluoro-4-nitrophenoxy)quinolin-7-ol 

Relevant articles and documents

Discovery of a potent, selective, and orally bioavailable c-met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl) -5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)

Deregulation of the receptor tyrosine kinase c-Met has been implicated in human cancers. Pyrazolones with N-1 bearing a pendent hydroxyalkyl side chain showed selective inhibition of c-Met over VEGFR2. However, studies revealed the generation of active, n

Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate

A series of 1,6-naphthyridinone-based MET kinase inhibitors bearing quinoline moiety in block A were designed and synthesized based on the structures of Cabozantinib and our reported compound IV. Extensive SAR and DMPK studies led to the identification of 20j, a potent and orally bioavailable MET kinase inhibitor with favorable kinase selectivity. More importantly, 20j exhibited statistically significant tumor growth inhibition (Tumor growth inhibition/TGI of 131%, 4/6 partial regression/PR) in the U-87 MG xeograft model, which is superior to that of Cabozantinib (TGI of 97%, 2/6 PR), and significantly better than that of compound IV (TGI of 15%, 0/6 PR) at the same dose (12.5 mg/kg). Combined with favorable in vitro potency, kinase selectivity, pharmacokinetic profile and in vivo efficacy, the promising antitumor drug candidate 20j has subsequently advanced into preclinical research.

N - acyl aniline c - Met kinase inhibitor preparation method and use thereof

The invention relates to the field of pharmaceutical chemistry, and in particular relates to N - acyl aniline derivatives, process for their preparation, pharmaceutical compositions containing these compounds and their use for medical purposes, in particu

AURORA KINASE MODULATORS AND METHODS OF USE

The present invention relates to chemical compounds having a general formula I wherein A1-6, L1, L2, R1, R4-6 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds and methods of treating disease states related to the activity of Aurora kinase.